Preclinical Ophthalmic Drug Development Services ace

Get in Touch ace

* First Name:
* Last Name:
* Business Email:
Phone:
Company/Institution:
Job Title:
* Services of Interest: Preclinical Ophthalmic Imaging Services
When do you expect your project to start?
Project Description:
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

Preclinical Ophthalmic Imaging Services

Ace Therapeutics provides preclinical ophthalmic imaging services integrated with our in vivo ocular disease animal models across multiple species. Our team applies a suite of complementary imaging modalities to longitudinally quantify structural and vascular endpoints, supporting efficacy evaluation, ocular safety assessment, and mechanism-of-action studies. Imaging modality selection and endpoint definitions are aligned with the biology of the disease model and the study objectives. Data acquisition and analysis are conducted by the same scientific team to ensure consistent readouts and reporting tailored to each program's requirements.

Value of Ophthalmic Imaging in Preclinical Studies

Ophthalmic imaging has become a cornerstone of preclinical ocular research because it enables noninvasive, repeatable visualization of the eye with high spatial resolution and complementary contrasts. In animal models, multimodal imaging allows investigators to follow disease onset and progression in the same subjects, quantify structural and vascular phenotypes over time, and relate these changes to pharmacologic effects with fewer terminal time points. With well-defined endpoints and standardized analysis, imaging data are easier to compare across groups and timepoints, improving study interpretability and reproducibility.

Fig. 1. Fluorescein Angiography (FA) and Optical Coherence Tomography (OCT) Imaging Results. Fig. 1. Images obtained from fluorescein angiography (FA) and optical coherence tomography (OCT) imaging. (Chen CW, et al., 2022)

Our Preclinical Ophthalmic Imaging Capabilities

To support preclinical ophthalmology studies, our scientific team provides comprehensive imaging services using ocular disease animal models across multiple species. We offer customized imaging protocols and quantitative endpoints aligned with your study goals to enable robust pharmacology assessment and disease mechanism research.

Imaging Technique	Service Description
Color Fundus Photography	We provide color fundus photography to document posterior segment appearance and lesion morphology over time, supporting baseline phenotyping and longitudinal monitoring in ocular disease animal models.
Optical Coherence Tomography (OCT)	We use OCT to generate quantitative structural readouts from the eye, supporting longitudinal assessment of disease progression and pharmacology-related changes in in vivo ocular disease studies.
Fluorescein Angiography (FA)	For vascular-driven ocular models, we perform FA to assess vascular phenotype and dynamic changes, including leakage patterns and perfusion-related features, with endpoints tailored to the study design.
Fundus Autofluorescence (FAF)	We provide FAF imaging to track fundus changes over time and support phenotyping and longitudinal monitoring in animal models where the outer retina and retinal pigment epithelium (RPE) are key features.
Slit-Lamp Biomicroscopy	We conduct slit-lamp biomicroscopy with standardized image documentation to support consistent evaluation of study-relevant ocular findings over time.
Ocular Surface Fluorescein Staining	For ocular surface–focused studies, we incorporate fluorescein staining to visualize epithelial disruption and surface integrity, supporting standardized scoring and longitudinal follow-up throughout the study.

Why Choose Us

One team runs the ocular disease model and the imaging workflow, minimizing handoffs and keeping endpoints aligned.
Multiple imaging approaches can be combined within the same study to capture both structural and vascular readouts.
Repeatable longitudinal imaging supports consistent follow-up and clear time-course interpretation.
Ophthalmology-focused scientists support study planning, image acquisition, analysis, and reporting.

Ace Therapeutics is a research service provider specializing in ophthalmology, combining ocular disease animal model development with quantitative ophthalmic imaging to support preclinical studies. Contact us to discuss your study objectives and learn how our integrated model development and imaging services can support your program.

References

Batista A, Guimarães P, Serranho P, et al. Retinal imaging in animal models: Searching for biomarkers of neurodegeneration. Front Ophthalmol (Lausanne). 2023 Apr 6; 3: 1156605.
Chen CW, Potenski AM, Colón Ortiz CK, et al. In vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility. J Vis Exp. 2022 Apr 21; (182): 10.3791/63782.

For Research Use Only.